NANJING, China – November 7, 2025 – Shanghai MediumBank Biotechnology Co., Ltd. (MediumBank) held a groundbreaking ceremony for its Phase II Bioprocess Reagents Production Base in Nanjing today. The event took place at the Nanjing New Industrial-Tairong Bioreagent Industrial Cluster.
Senior government officials from Nanjing and Jiangning District attended the ceremony, alongside the company's partners, investors, and clients.
Mr. Wang Yantao, Founder, Chairman, and CEO of MediumBank, stated that the new base is a strategic step to enhance supply chain resilience and support the domestic biopharmaceutical industry's need for core upstream materials.
The ceremony included speeches from client and investor representatives, who expressed confidence in MediumBank's products and growth strategy.
Local government representatives reaffirmed their support for the project and its role in strengthening the regional biopharmaceutical cluster.
During the event, MediumBank signed a strategic cooperation agreement with Zhejiang Quansheng Biotechnology Co., Ltd. to collaborate in the cell therapy field.
The ceremony concluded with a formal initiation act, marking the official start of construction for the Phase II base.
